Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan

doi:10.1007/s12072-020-10122-1

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/23360

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23360

Title:	Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan
Authors:	Yen, FS;Wei, JCC;Yip, HT;Hwu, CM;Hou, MC;Hsu, CC
Keywords:	Management;Type 2 diabetes mellitus;Compensated liver cirrhosis;Decompensated cirrhosis;Mortality;Cardiovascular events;Hepatic outcomes;Hepatic failure;Variceal bleeding;Hepatocellular carcinoma
Date:	2021
Issue Date:	2022-08-05T09:36:00Z (UTC)
Publisher:	SPRINGER
ISSN:	1936-0533
Abstract:	Background/purpose Management of type 2 diabetes mellitus (T2DM) in patients with liver cirrhosis is complex and suboptimal, but no clinical trial has adequately investigated antidiabetic drug use for such patients. We evaluate the risk of mortality, cardiovascular events, and hepatic outcomes between dipeptidyl peptidase-4 (DPP-4) inhibitor users and nonusers in patients with type 2 diabetes mellitus (T2DM) and cirrhosis. Methods We selected 2828 paired propensity score matched DPP-4 inhibitor users and nonusers from a cohort of T2DM with compensated liver cirrhosis between January 1, 2007, and December 31, 2012. Cox proportional hazards models were used to assess the risk of main outcomes for DPP-4 inhibitor users. Results The incidence rate of decompensated cirrhosis during follow-up was 2.20 and 1.53 per 100 patient-years (adjusted hazard ratio [aHR] 1.35, 95% confidence interval [CI] 1.03-1.77) for DPP-4 inhibitor users and nonusers, respectively. The aHRs (95% CI) of variceal bleeding and hepatic failure were 1.67 (1.11-2.52) and 1.35 (1.02-1.79), respectively, for DPP-4 inhibitor users over nonusers. The risk of all-cause mortality, hepatocellular carcinoma, and major cardiovascular events between DPP-4 inhibitor users and nonusers were not statistically different. Conclusions This study found that DPP-4 inhibitor users were associated with higher risks of decompensated cirrhosis and hepatic failure than did nonusers among patients with T2DM and compensated liver cirrhosis. We must continue to search for appropriate antidiabetic drugs for patients with liver cirrhosis.
URI:	http://dx.doi.org/10.1007/s12072-020-10122-1 https://www.webofscience.com/wos/woscc/full-record/WOS:000606722200001 https://ir.csmu.edu.tw:8080/handle/310902500/23360
Relation:	HEPATOLOGY INTERNATIONAL ,2021,v15,issue 1, P179-190
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	222	View/Open

Loading...